IpAuctions Selling Liver Disease Therapeutic Patent Portfolio
Posted on: Thursday, 17 July 2008, 15:01 CDT
IpAuctions, Inc. will auction the worldwide biotherapeutic patents previously owned by Cell Works Inc., a Maryland-based biotech company, and acquired by CellPoint Diagnostics, Inc., based in Mountain View, Calif. These patents primarily consist of organ-targeted drug delivery systems to combat liver disease.
Fifteen major U.S. and worldwide medical patents and applications in three major treatment areas will be auctioned, including one associated with a liver cancer therapeutic drug that has been granted orphan drug status by the Food and Drug Administration (FDA). The orphan drug status designation is given to provide special benefits to encourage development of drugs to treat conditions having a prevalence of less than 200,000 cases in the U.S. The worldwide market for a liver cancer therapeutic is quite large, however, and U.S. orphan drug status includes other possible benefits such as research grants, assistance in negotiating the regulatory process and special tax credits. The IP portfolio currently for sale by IpAuctions consists of a therapeutic platform for a ligand-directed drug delivery system that can target the liver or the renal system for greater specificity and efficacy, with less toxicity to the patient.
The patents and applications in this portfolio describe the use of a ligand-directed drug delivery system. The system consists of a ligand (a carbohydrate that is bound and internalized by a cell/tissue-specific receptor on the cell surface) that serves as a guidance system to direct the delivery of the conjugated drug to the targeted organ, according to information provided by Cell Works Inc. of Maryland, the previous owner of this IP portfolio.
IpAuctions, Inc.(R) (www.ipauctions.com) is the leading online auction firm specializing in the sale of intellectual property assets. The firm has a proprietary database of over 7,000 attorneys, corporate and private buyers, and venture capitalists, who wish to maximize their IP assets. IpAuctions, Inc. is a member of the National Auctioneers Association and the ABI.
For more information about this sale or other intellectual property, please contact Joseph Popolo (CEO) or Davel Foote (Mrktg), IpAuctions, Inc. at 866-826-1300 or 348 Mill St., Reno, NV 89501 USA. Email: info@ipauctions.com.
Source: Business Wire
Related Articles
- Ikaria(R) Acquires North American Rights to LUCASSIN(R) From Orphan Therapeutics
- Orphan Therapeutics Initiates Filing of Rolling NDA for Liver Drug
- Orphan Therapeutics Announces Initiation of Rolling NDA Submission for LUCASSIN(R) (Terlipressin) for the Treatment of Hepatorenal Syndrome Type 1
- Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status By U.S. FDA
- Congressman Edward Markey Says U.S. Drug Safety System is 'Broken' at 3rd Annual Post-Approval Summit
- Emergis and Infoway Complete Preferred Solution Vendor Agreement for Drug Information Systems
- Even With Bush Veto, Stem Cell Research Thrives -- Offering Hope for Americans Anticipating Stem Cell-Based Therapies, PrimeCell(TM) Therapeutics Chief Researcher Says
- The Development and Evaluation of an Integrated Electronic Prescribing and Drug Management System for Primary Care
- MedVentive Releases Latest Version of PRISM Drug Substitution System
- Protein Design Labs and Orphan Therapeutics Report Fast Track Designation for Terlipressin in Type 1 Hepatorenal Syndrome
 |
 |
User Comments (0)
RSS Feeds